344 related articles for article (PubMed ID: 31935290)
1. Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia.
Harvey RC; Tasian SK
Blood Adv; 2020 Jan; 4(1):218-228. PubMed ID: 31935290
[TBL] [Abstract][Full Text] [Related]
2. Clinical screening for Ph-like ALL and the developing role of TKIs.
Tran TH; Tasian SK
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):594-602. PubMed ID: 36485164
[TBL] [Abstract][Full Text] [Related]
3. Ph-like acute lymphoblastic leukemia.
Tran TH; Loh ML
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):561-566. PubMed ID: 27913529
[TBL] [Abstract][Full Text] [Related]
4. Why and how to treat Ph-like ALL?
Roberts KG
Best Pract Res Clin Haematol; 2018 Dec; 31(4):351-356. PubMed ID: 30466746
[TBL] [Abstract][Full Text] [Related]
5. Philadelphia-like acute lymphoblastic leukemia: the journey from molecular background to the role of bone marrow transplant-review article.
Alghandour R; Sakr DH; Shaaban Y
Ann Hematol; 2023 Jun; 102(6):1287-1300. PubMed ID: 37129698
[TBL] [Abstract][Full Text] [Related]
6. Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant.
Samra B; Kantarjian HM; Sasaki K; Alotaibi AS; Konopleva M; O'Brien S; Ferrajoli A; Garris R; Nunez CA; Kadia TM; Short NJ; Jabbour E
Acta Haematol; 2021; 144(3):285-292. PubMed ID: 33238261
[TBL] [Abstract][Full Text] [Related]
7. Ph-like acute lymphoblastic leukemia in adults: understanding pathogenesis, improving outcomes, and future directions for therapy.
Aldoss I; Gu Z; Afkhami M; Mokhtari S; Pullarkat V
Leuk Lymphoma; 2023 Jun; 64(6):1092-1101. PubMed ID: 37021793
[TBL] [Abstract][Full Text] [Related]
8. The biology of Philadelphia chromosome-like ALL.
Roberts KG
Best Pract Res Clin Haematol; 2017 Sep; 30(3):212-221. PubMed ID: 29050694
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase inhibitor use in pediatric Philadelphia chromosome-positive acute lymphoblastic anemia.
Hunger SP
Hematology Am Soc Hematol Educ Program; 2011; 2011():361-5. PubMed ID: 22160058
[TBL] [Abstract][Full Text] [Related]
10. Has Ph-like ALL Superseded Ph+ ALL as the Least Favorable Subtype?
Tran TH; Tasian SK
Best Pract Res Clin Haematol; 2021 Dec; 34(4):101331. PubMed ID: 34865703
[TBL] [Abstract][Full Text] [Related]
11. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic Hematopoietic Stem Cell Transplantation, Especially Haploidentical, May Improve Long-Term Survival for High-Risk Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era.
Xue YJ; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1611-1620. PubMed ID: 30537550
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute.
Kidoguchi K; Ureshino H; Kizuka-Sano H; Yamaguchi K; Katsuya H; Kubota Y; Ando T; Miura M; Takahashi N; Kimura S
Int J Hematol; 2021 Aug; 114(2):199-204. PubMed ID: 33907977
[TBL] [Abstract][Full Text] [Related]
14. Philadelphia chromosome-like acute lymphoblastic leukemia: A review of the genetic basis, clinical features, and therapeutic options.
Khan M; Siddiqi R; Tran TH
Semin Hematol; 2018 Oct; 55(4):235-241. PubMed ID: 30502852
[TBL] [Abstract][Full Text] [Related]
15. Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia.
King AC; Pappacena JJ; Tallman MS; Park JH; Geyer MB
Leuk Res; 2019 Apr; 79():27-33. PubMed ID: 30831480
[TBL] [Abstract][Full Text] [Related]
16. Genetic Alterations and Therapeutic Targeting of Philadelphia-Like Acute Lymphoblastic Leukemia.
Iacobucci I; Roberts KG
Genes (Basel); 2021 May; 12(5):. PubMed ID: 34062932
[TBL] [Abstract][Full Text] [Related]
17. Emerging tyrosine kinase inhibitors for the treatment of adult acute lymphoblastic leukemia.
Ansuinelli M; Cesini L; Chiaretti S; FoĆ R
Expert Opin Emerg Drugs; 2021 Sep; 26(3):281-294. PubMed ID: 34259120
[No Abstract] [Full Text] [Related]
18. Susceptibility of Ph-positive all to TKI therapy associated with Bcr-Abl rearrangement patterns: a retrospective analysis.
Jing Y; Chen H; Liu M; Zhou M; Guo Y; Gao C; Wang Q; Li H; Zhao Y; Bo J; Huang W; Zhu H; Zhang Y; Yu L
PLoS One; 2014; 9(11):e110431. PubMed ID: 25415187
[TBL] [Abstract][Full Text] [Related]
19. Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
Xu N; Li YL; Li X; Zhou X; Cao R; Li H; Li L; Lu ZY; Huang JX; Fan ZP; Huang F; Zhou HS; Zhang S; Liu Z; Zhu HQ; Liu QF; Liu XL
J Hematol Oncol; 2016 Apr; 9():40. PubMed ID: 27090891
[TBL] [Abstract][Full Text] [Related]
20. Treatment Selection for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors.
Ma Y; Zhang Q; Kong P; Xiong J; Zhang X; Zhang C
Chemotherapy; 2019; 64(2):81-93. PubMed ID: 31390613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]